

DAFTAR PUSTAKA

- Abdullah, & Asim, Z. (2025). Cost effectiveness of mono, dual, and triple therapy of antihypertensive drugs: a retrospective cohort study. *Cost Effectiveness and Resource Allocation*, 23(1). <https://doi.org/10.1186/s12962-025-00614-y>
- Acharya, Y., Paudel, P., Regmi, U., Paneru, B., Shrestha, A., & Karmacharya, B. M. (2025). *Assessment of COVID- hospitalisation cost and its associated factors in Nepal: a descriptive cross-sectional study*. 1–8. <https://doi.org/10.1136/bmjopen-2024-091862>
- Adediran, E., Owens, R., Gardner, E., Curtin, A., Stuligross, J., Forbes, D., Wang, J., & Ose, D. (2024). *Risk factors of undiagnosed and uncontrolled hypertension in primary care patients with hypertension : a cross-sectional study*. 1–14.
- Afandi, A., Lestari, S., Waluyo, U. N., & Waluyo, U. N. (2023). *Pro Health Jurnal Ilmiah Kesehatan PREVALENSI DAN RISK ASSESSMENT KEJADIAN HIPERTENSI*. 5(2), 364–368.
- Agustin, E. D., Vita, L., Dewi, I., Hanifah, I. R., Studi, P., Farmasi, S., Farmasi, F., Setia, U., & Surakarta, B. (2023). *Analisis Efektivitas Biaya Pengobatan Golongan Statin dalam Manajemen Penyakit Jantung Koroner Di RSUD Kota Madiun 2021 / 2022*. 9(2), 282–290.
- Aldisi, R. S., Alsamman, A. M., Krawitz, P., Maj, C., & Zayed, H. (2025). Identification of novel proteomic biomarkers for hypertension : a targeted approach for precision medicine. *Clinical Proteomics*. <https://doi.org/10.1186/s12014-024-09519-z>
- Almehwari, S. A., Almalki, I. S., Abumilha, B. A., & Altharwi, B. H. (2024). *Improving Hospital Efficiency and Cost Management : A Systematic Review and Meta- Analysis*. 16(10). <https://doi.org/10.7759/cureus.71721>
- Anggraini, D., Oktora, M. Z., & Hasni, D. (n.d.). *Peran Indeks Aterogenik sebagai Penanda Komplikasi pada Diabetes Melitus Tipe 2 : Tinjauan Pustaka*. 91–99.
- Azari, S., Pourasghari, H., Rezaei, M. A., Behzadifar, M., & Salehbeigi, S. (2025). *Fair pricing , fair access ; a systematic review of cost-effectiveness of new*

hyperlipidemia injectable medication in developing countries. 3.

- Azizah, S. A., & Novrianti, I. (2022). *Pharmacotherapy Of Diabetic Mellitus : A Review Review : Farmakoterapi Diabetes Melitus*. 5(2), 80–91.
- Bilcke, J., & Beutels, P. (2022). *Generating , Presenting , and Interpreting Cost-Effectiveness Results in the Context of Uncertainty : A Tutorial for Deeper Knowledge and Better Practice*. 42(4), 421–435. <https://doi.org/10.1177/0272989X211045070>
- Blumenthal, R. S., Buroker, A. B., & Sq, E. (2019). *2019 ACC / AHA Guideline on the Primary Prevention of Cardiovascular Disease*. <https://doi.org/10.1016/j.jacc.2019.03.010>
- Care, D., & Suppl, S. S. (2024). 5 . *Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes : Standards of Care in Diabetes — 2024*. 47(January), 77–110.
- Care, D., Suppl, S. S., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Leon, J., Lyons, S. K., Perry, M. Lou, Prahalad, P., & Pratley, R. E. (2023). 10 . *Cardiovascular Disease and Risk Management : Standards of Care in Diabetes — 2023*. 46(January), 158–190.
- Chen, M., Pan, D., Pan, T., Liu, Z., Geng, Y., Ma, X., & Liang, P. (2025). Impact analysis of DRG payment reform on hospitalization expenses and length of stay for lung cancer inpatients (2019–2023). *Frontiers in Health Services*, 5(October), 1–10. <https://doi.org/10.3389/frhs.2025.1661995>
- Chow, R., Simone, C. B., Prsic, E. H., & Shin, H. J. (2022). Cost-effectiveness analysis of statins for the treatment of hospitalized COVID-19 patients. *Annals of Palliative Medicine*, 11(7), 2285–2290. <https://doi.org/10.21037/apm-21-2797>
- Climent, E., Benaiges, D., & Pedro-botet, J. (2021). *Hydrophilic or Lipophilic Statins ?* 8(May), 1–11. <https://doi.org/10.3389/fcvm.2021.687585>
- CO. (n.d.).
- Cohen, J. B., & Collins, K. J. (2025). *2025 AHA / ACC / AANP / AAPA / ABC / ACCP / ACPM / AGS / AMA / ASPC / NMA / PCNA / SGIM Guideline for the Prevention , Detection , Evaluation , and Management of High Blood Pressure in Adults*. 86(18). <https://doi.org/10.1016/j.jacc.2025.05.007>

- Colquhoun, D., & Colquhoun, D. (2014). *An investigation of the false discovery rate and the misinterpretation of p -values Subject Areas : Author for correspondence :*
- Damayanti, V. W., Yonata, A., Kurniawaty, E., Kedokteran, F., Lampung, U., Dalam, B. P., Kedokteran, F., Lampung, U., Biokimia, B., Kedokteran, F., & Lampung, U. (2023). *Hipertensi pada Diabetes Melitus : Patofisiologi dan Faktor Risiko Hypertension in Diabetes Melitus : Pathophysiology and Risk Factor*. 14(November), 1253–1257.
- Desoky, A. A., Mostafa, N. M., & Abdellah-alawi, M. H. M. (2025). *Telehealth and challenges of statin adherence in patients with diabetes : a randomized controlled trial*.
- Dhaba, F. A., Alemu, W. A., Kitila, F. L., Tolla, K. S., Alene, A., Wendimagegn, Z. S., & Getahun, K. A. (2025). *Statin utilization and its predictors for the primary prevention of cardiovascular disease among type 2 diabetic patients in a resource-limited setting*. July, 1–12. <https://doi.org/10.3389/fendo.2025.1472300>
- Disorders, M. (2024). *Comparative Effectiveness of Statin Therapy in Reducing Cardiovascular Events*. <https://doi.org/10.24966/DMD-201X/100051>
- Dressel, A., Fath, F., Krämer, B. K., Klose, G., & März, W. (2025). *Statins for primary prevention of cardiovascular disease in Germany : benefits and costs Statins for Primary Prevention of Cardiovascular Disease in Germany : Benefits and Costs. Clinical Research in Cardiology*. <https://doi.org/10.1007/s00392-025-02608-5>
- Drexler, Y., & Yang, E. (2025). *Population Impact of Using the PREVENT Equations to Guide the Management of Stage 1 Hypertension in the United States*. 3–5. <https://doi.org/10.1161/JAHA.124.038915>
- Dusetzina, S. B., Besaw, R. J., Whitmore, C. C., Li, T. J. M., & Sinaiko, A. D. (2023). *Cost-Related Medication Nonadherence and Desire for Medication Cost Information Among Adults Aged 65 Years and Older in the US in 2022*. 6(5), 1–12. <https://doi.org/10.1001/jamanetworkopen.2023.14211>
- Eisavi, M. (2021). *The Cost - Effectiveness and Cost - Utility of Statin Drug for the Treatment of Patients with Cardiovascular Disease , A Systematic Review*.

<https://doi.org/10.4103/ijpvm.IJPVM>

- Elshafeey, A. (2025). Therapeutic Management of LDL-C: Efficacy and Economic Impact Assessment. *Journal of Cardiovascular Development and Disease*, 12(5), 1–21. <https://doi.org/10.3390/jcdd12050196>
- Esha, P., Dewi, N., Thavorncharoensap, M., & Rahajeng, B. (2024). Cost – utility analysis of using high - intensity statin among post - hospitalized acute coronary syndrome patients. *The Egyptian Heart Journal*. <https://doi.org/10.1186/s43044-024-00478-2>
- Farmasi, P. S., Kesehatan, F., Bumigora, U., & Farmasi, F. (2021). *Pengaruh Komorbid dan Jenis Terapi Terhadap Outcome Kolesterol Total Pasien Dislipidemia*. 11(3), 153–163.
- Filppula, A. M., Hirvensalo, P., Parviainen, H., Ivaska, V. E., Lönnberg, K. I., Deng, F., Kurkela, M., Neuvonen, M., & Niemi, M. (2021). *Title Page Comparative hepatic and intestinal metabolism and pharmacodynamics of statins # Running Title Page*. April. <https://doi.org/10.1124/dmd.121.000406>
- Gandjour, A. (2025). *Health-economic evaluation of statins versus lifestyle changes for cardiovascular disease prevention*. 26, 1–13. <https://doi.org/10.1371/journal.pone.0331176>
- Guideline, C. (2024). *Clinical practice guideline for the management of hypertension in* (Vol. 137, Issue 24).
- Guideline, E. (2016). *JNC 8 : Evidence-based Guideline Penanganan Pasien Hipertensi Dewasa*. 43(1), 54–59.
- Guidelines, P. (2024). *European Journal of Internal Medicine*. 126(May), 1–15. <https://doi.org/10.1016/j.ejim.2024.05.033>
- Harrison, D. G., & Touyz, R. M. (2025). *Hypertension Editors ' View of the 2025 Guideline for the Prevention , Detection , Evaluation , and Management of High Blood Pressure in Adults*. October, 193–195. <https://doi.org/10.1161/HYPERTENSIONAHA.125.25467>
- Havers, F., Bramley, A. M., Finelli, L., Reed, C., Self, W. H., Trabue, C., Fakhran, S., Balk, R., Courtney, D. M., Girard, T. D., Anderson, E. J., Grijalva, C. G., Edwards, K. M., Wunderink, R. G., & Jain, S. (2016). Statin Use and Hospital Length of Stay among Adults Hospitalized with Community-acquired

- Pneumonia. *Clinical Infectious Diseases*, 62(12), 1471–1478.
<https://doi.org/10.1093/cid/ciw174>
- Health, P. D. (2022). *PLOS DIGITAL HEALTH A systematic review of the prediction of hospital length of stay: Towards a unified framework*.
<https://doi.org/10.1371/journal.pdig.0000017>
- Hedou, J., Mendes, G., Bellan, G., El Khoury, D., & Verdonk, F. (2025). Impact of postoperative complications on cost and length of stay: multicentre prospective clinical study. *The British Journal of Surgery*, 113(1), 1–2.
<https://doi.org/10.1093/bjs/znaf290>
- Ho, H. V, Patel, H., Ahmed, M., Eddib, A., Modi, F., Sorresso, D., Mhaskar, R., Phrathep, D., & Oyesanmi, O. (2023). A Retrospective Cohort Study Assessing the Impact of Statin Therapy on Hospital Length of Stay and Inpatient Mortality in COVID-19 Patients. *HCA Healthcare Journal of Medicine*, 4(5), 369–375. <https://doi.org/10.36518/2689-0216.1546>
- Husereau, D., Drummond, M., Augustovski, F., Bekker-grob, E. De, Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., Mauskopf, J., Mullins, C. D., & Petrou, S. (2022). *Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement : updated reporting guidance for health economic evaluations*. 2022(Cheers), 1–7. <https://doi.org/10.1136/bmj-2021-067975>
- Husnawati, H., Rusnedy, R., Fadillah, M., & Zulfitri, R. (2026). *Potential Drug Interactions in Outpatients with Hypertension and Comorbid Type 2 Diabetes Mellitus at Arifin Achmad Regional General Hospital Riau Province*. 14(1), 66–73.
- Id, A. Y., Mohammadi, F., Rabizadeh, S., Esteghamati, A., & Id, M. N. (2023). *Decreasing trend of blood lipid profile in type 2 diabetes : Not a promising change in HDL-C , a serial cross-sectional study*. 1–15.
<https://doi.org/10.1371/journal.pone.0293410>
- Jaam, M. (2023). *Comparative efficacy and safety among high-intensity statins . Systematic Review and Meta-Analysis*. <https://doi.org/10.57264/cer-2022-0163>
- Jiao, B., Veenstra, D. L., Lee, W., Carlson, J. J., & Devine, B. (2020). *The use of*

real-world evidence in ICER ' s scoping process and clinical evidence assessments. 26(12), 1590–1595.

- Karnjanapiboonwong, A., & Anothaisintawee, T. (2020). Diagnostic performance of clinic and home blood pressure measurements compared with ambulatory blood pressure : a systematic review and meta - analysis. *BMC Cardiovascular Disorders*, 1–17. <https://doi.org/10.1186/s12872-020-01736-2>
- Kim, H. (2017). *Statistical notes for clinical researchers : Chi-squared test and Fisher ' s exact test.* 7658, 152–155.
- Klimes, J., Vocelka, M., Dolezal, T., & Kruntoradova, K. (2013). Cost-Effectiveness Analysis of Atorvastatin Compared to Simvastatin in the Prevention of Cardiovascular Diseases in the Czech Republic. *Value in Health*, 16(7), A528. <https://doi.org/10.1016/j.jval.2013.08.1292>
- Kohli-lynch, C. N., Lewsey, J., Boyd, K. A., French, D. D., Jordan, N., Moran, A. E., Sattar, N., Preiss, D., & Briggs, A. H. (2022). *Beyond 10-Year Risk : A Cost-Effectiveness Cardiovascular Disease.* 1312–1323. <https://doi.org/10.1161/CIRCULATIONAHA.121.057631>
- Kristin, E., Krisdinarti, L., Yasmina, A., Pratiwi, W. R., & Febrinasari, R. P. (2022). *Medication Persistence to Lipid-Lowering Agents as Cost-Saving Opportunities in Indonesian Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention.* 32(2), 291–298.
- Kriswiastiny, R., Hidayat, N. A., Mustofa, F. L., & Hermawan, D. (2022). *Hubungan Lama Menderita Diabetes Melitus dan Kadar Gula Darah dengan Kadar Kolesterol Total Pada Pasien Diabetes Melitus Tipe 2 Di Rumah Sakit Pertamina Bintang Amin Husada Bandar Lampung Tahun 2021* 12, 486–494.
- Laakso, M., & Silva, L. F. (2023). *Statins and risk of type 2 diabetes : mechanism and clinical implications.* September, 1–10. <https://doi.org/10.3389/fendo.2023.1239335>
- Latif, W. D., Aswad, M., & Bahar, M. A. (2022). Perbandingan Efektivitas Klinik Simvastatin dan Atorvastatin Terhadap Profil Lipid Darah: Studi Kasus di Rumah Sakit Universitas Hasanuddin. *Jurnal Sains Farmasi & Klinis*, 9(1), 34. <https://doi.org/10.25077/jsfk.9.1.34-41.2022>
- Leo, G. Di, & Sardanelli, F. (2020). *Statistical significance : p value , 0 . 05*

threshold , and applications to radiomics — reasons for a conservative approach.

- Li, J., Zhao, S., Zhao, D., Lu, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S., & Wang, Z. (2023). *2023 Chinese guideline for lipid management. August*, 1–33. <https://doi.org/10.3389/fphar.2023.1190934>
- Liao, C. Te, Toh, H. S., Sun, L., Yang, C. T., Hu, A., Wei, D., Melgarejo, J., & Zhang, Z. Y. (2023). Cost-effectiveness of Intensive vs Standard Blood Pressure Control Among Older Patients With Hypertension. *JAMA Network Open*, 6(2), 1–13. <https://doi.org/10.1001/jamanetworkopen.2023.0708>
- Lim, Y. C., Lee, E. K., & Park, M. H. (2023). Factors influencing drug switching and changes in low - density lipoprotein - cholesterol levels with atorvastatin : a real - world observational study. *Lipids in Health and Disease*, 1–9. <https://doi.org/10.1186/s12944-023-01903-2>
- Loh, W. J., Soh, H. S., & Tun, M. H. (2024). *Elevated remnant cholesterol and non-HDL cholesterol concentrations from real-world laboratory results: a cross-sectional study in Southeast Asians. February*, 1–11. <https://doi.org/10.3389/fcvm.2024.1328618>
- Ma, K. J., Hsu, Y. C., Pan, W. W., Chou, M. H., Chung, W., & Wang, J. Y. (2025). Effects of emergency department length of stay on inpatient utilization and mortality. *Health Economics Review*, 15(1). <https://doi.org/10.1186/s13561-025-00598-8>
- María, J., Pintó, X., Armario, P., Masana, L., Real, J. T., Valdivielso, P., Arrobas-velilla, T., Baeza-trinidad, R., Calmarza, P., Cebollada, J., Civera-andrés, M., Cuende, J. I., Díaz-díaz, J. L., Espíldora-hernández, J., Fernández, J., Guijarro, C., Jericó, C., Laclaustra, M., Lahoz, C., ... Puzo, J. (2024). *CONSENSUS STATEMENT SEA 2024 Standards for Global Control of Vascular Risk. 36*. <https://doi.org/10.1016/j.artere.2024.06.001>
- Marsellinda, E., Klinis, P. F., Kedokteran, F., & Baiturrahmah, U. (2022). Terapi obat dislipidemia pada pasien diabetes melitus di RSI Siti Rahmah .(01), 15–20.
- May, P., Normand, C., Noreika, D., Skoro, N., & Cassel, J. B. (2021). Using predicted length of stay to define treatment and model costs in hospitalized

- adults with serious illness: an evaluation of palliative care. *Health Economics Review*, 11(1), 1–11. <https://doi.org/10.1186/s13561-021-00336-w>
- Mccarthy, C. P., Force, T., States, C. U., Bruno, R. M., France, T. F. C., Brouwers, S., Canavan, M. D., Ceconi, C., Maria, R., Canada, S. S. D., Ferro, C. J., Kingdom, U., Hanssen, H., Harris, J., Kingdom, U., Lauder, L., Mcmanus, R. J., Kingdom, U., Molloy, G. J., ... Pedro, M. M. (2024). *2024 ESC Guidelines for the management of elevated blood pressure and hypertension Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)*. 3912–4018. <https://doi.org/10.1093/eurheartj/ehae178>
- Melitus, D., Pada, T., Geriatri, P., Kedokteran, F., & Lampung, U. (2024). *Sains Medisina*. 2(5), 142–147.
- Merino-sanjuan, M., García-arieta, A., Mangas-, V., & Reig-l, J. (2022). *Biomedicine & Pharmacotherapy A physiologically based pharmacokinetic model for open acid and lactone forms of atorvastatin and metabolites to assess the drug-gene interaction with SLCO1B1 polymorphisms Sanju a*. 156(October). <https://doi.org/10.1016/j.biopha.2022.113914>
- Michel Farnier. (2020). *Investigations Efficacy of Atorvastatin Compared With Simvastatin in Patients With Hypercholesterolemia*. 9.
- Michel, R., Ansgar, A., Waldemar, B., Sandor, B., & Walter, W. (2021). *Cost-effectiveness analysis of statins in primary care: results from the Arteris cohort study*. April, 1–11. <https://doi.org/10.4414/smw.2021.20498>
- Mihaylova, B., Wu, R., Zhou, J., Williams, C., Schlackow, I., Emberson, J., Reith, C., & Keech, A. (2024). Articles Lifetime effects and cost-effectiveness of standard and higher- intensity statin therapy across population categories in the UK : a microsimulation modelling study. *The Lancet Regional Health - Europe*, 40, 100887. <https://doi.org/10.1016/j.lanep.2024.100887>
- Moradi, S., Najafpour, Z., Cheraghian, B., Keliddar, I., & Mombeyni, R. (2024). The Extra Length of Stay, Costs, and Mortality Associated With Healthcare-Associated Infections: A Case-Control Study. *Health Science Reports*, 7(11), 1–8. <https://doi.org/10.1002/hsr2.70168>

- Morton, J. I., Marquina, C., Lloyd, M., Watts, G. F., Zoungas, S., Liew, D., & Ademi, Z. (2024). Lipid - Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost - Effectiveness Analysis. *Pharmacoeconomics*, 42(1), 91–107. <https://doi.org/10.1007/s40273-023-01306-2>
- Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Li, R. L. P., Goldstein, L. B., Chin, C., Tannock, L. R., Miller, M., Raghuveer, G., Duell, P. B., Brinton, E. A., Pollak, A., & Braun, L. T. (2019). *A Scientific Statement From the American Heart Association*. <https://doi.org/10.1161/ATV.0000000000000073>
- Oktaviana, A., Wijaya, D. P., Pramuntadi, A., & Heksaputra, D. (2024). *Prediction of Type 2 Diabetes Mellitus Using The K-Nearest Neighbor (K-NN) Algorithm Prediksi Penyakit Diabetes Melitus Tipe 2 Menggunakan Algoritma K-Nearest Neighbor (K-NN)*. 4(July), 812–818.
- Pancholia, A. K., Kumar, N., & Gupta, R. (2024). Laboratory evaluation of lipid parameters in clinical practice. *Indian Heart Journal*, 76(S1), S29–S32. <https://doi.org/10.1016/j.ihj.2024.02.002>
- Patel, K. K., Sehgal, V. S., & Kashfi, K. (2023). *Molecular targets of statins and their potential side effects: Not all the glitter is gold*. <https://doi.org/10.1016/j.ejphar.2022.174906>.Molecular
- Peningkatan, U., & Penyakit, K. (2024). Diabetes Melitus melalui edukasi dan skrining gula darah sewaktu 7(3), 641–648.
- Praskilevics, A., & Urtane, I. (2023). *National Trends in the Use of State-Reimbursed Lipid-Lowering Medications in Latvia (2012 – 2021)*.
- Ridker, P. M., Lei, L., Louie, M. J., Haddad, T., Nicholls, S. J., Lincoff, A. M., Libby, P., Nissen, S. E., & Outcomes, C. (2024). *Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance*. 28–35. <https://doi.org/10.1161/CIRCULATIONAHA.123.066213>
- Riset, A., Naufal, M. A., Za, H., Sri, K., Gayatri, W., Pramono, S. D., Hidayati, P. H., & Syamsu, R. F. (2022). *Hubungan antara Dislipidemia dengan Diabetes Melitus Tipe 2 di Rumah Sakit Ibnu Sina Makassar, Fakumi Medical Journal*,

- <https://fmj.fk.umi.ac.id/index.php/fmj/article/view/122>. 2(9), 668–677.
- Ruscica, M., Ferri, N., Corsini, A., & Sirtori, C. R. (2022). *Side effects of statins : from pathophysiology and epidemiology to diagnostic and therapeutic implications*. 3288–3304.
- Safei, I. (2021). *Miotoksisitas Statin : Kajian Stres Oksidatif Artikel Review*. 13, 68–73.
- Salma, W. O., & Kes, M. (n.d.). *Cetakan Pertama : 2026*.
- Schubert, J., Lindahl, B., Renlund, H., Yari, A., Ueda, P., James, S., Reading, S. R., Dluzniewski, P. J., Hamer, A. W., Jernberg, T., & Hagstro, E. (2021). *Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes : a Swedish nationwide cohort study*. 243–252. <https://doi.org/10.1093/eurheartj/ehaa1011>
- Sheinson, D., Dang, J., Shah, A., Meng, Y., Elsea, D., & Kowal, S. (2021). A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States. *Advances in Therapy*, 38(4), 1811–1831. <https://doi.org/10.1007/s12325-021-01654-5>
- Solnica, B., Sygitowicz, G., Sitkiewicz, D., & Józwiak, J. (2024). *2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders*.
- Steiger, K., Herrin, J., Swarna, K. S., Davis, E. M., Mccoy, R. G., & Continuum, U. S. R. (2024). *Disparities in Acute and Chronic Complications of Diabetes Disparities in Acute and Chronic Complications of Diabetes Along*. 47(5), 818–825.
- Sugianto, P. (2022). *The Effect of Simvastatin on Acute Phase Functional Outcome of Ischemic Stroke*. 2(1), 0–6.
- Sundvall, H., Vitols, S., Wallerstedt, S. M., & Fastbom, J. (2022). Prevalence and initiation of statin therapy in the oldest old — a longitudinal population - based study. *European Journal of Clinical Pharmacology*, 1459–1467. <https://doi.org/10.1007/s00228-022-03343-w>
- Supadmi, W., Sary, M. I., Gailea, A., Monica, L., Zukhruf, G., Hastuti, D., Farmasi, F., Ahmad, U., Yogyakarta, D., Farmasi, A., Yogyakarta, I., & Yogyakarta, A. A. (2024). *Hubungan Tingkat Pengetahuan dan Kepatuhan Pasien Hipertensi*

- di Apotek di Yogyakarta*. 20(2), 154–160.
- Suputra, P. A., Kedokteran, P., Ganesha, U. P., Kedokteran, P., Ganesha, U. P., Kedokteran, P., & Ganesha, U. P. (2021). *DIABETES MELITUS TIPE 2 : FAKTOR RISIKO , DIAGNOSIS , DAN*. 1(2), 114–120.
- Taheri, A., Khezri, R., Dehghan, A., Rezaeian, M., & Aune, D. (2024). Hypertension among persons with type 2 diabetes and its related demographic , socioeconomic and lifestyle factors in the Fasa cohort study. *Scientific Reports*, 1–9. <https://doi.org/10.1038/s41598-024-69062-7>
- Task, A., Members, F., Mancia, G., Co-chair, R. K., Burnier, M., Grassi, G., Januszewicz, A., Lorenza, M., Tsioufis, K., Agabiti-rosei, E., Abd, E., Algharably, E., Azizi, M., Benetos, A., Borghi, C., Brguljan, J., Cifkova, R., Coca, A., Cornelissen, V., ... Kjeldsen, S. E. (2023). *2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)*. 41(12).
- Tian, S., Li, Z., Bi, Y., Che, X., Feng, A., & Wang, Y. (2025). *Identifying pathways to cardiovascular mortality by causal graphical models and mediation analysis among hypertensive patients : insights from a prospective study*. 1–16.
- Vo, N. X., Thi, H., Nguyen, M., Phan, N. M., Pham, H. L., Bui, T. T., & Bui, T. T. (2025). *Cost-Effectiveness Analysis of Pitavastatin in Dyslipidemia : Cvd*, 1–16.
- Wang, W. (2024). *Analyzing lipid profiles and dyslipidemia prevalence in hypertensive patients : a cross-sectional study from primary community health institutions*. December, 1–14. <https://doi.org/10.3389/fmed.2024.1425414>
- Ward, R. (2020). *An Evaluation of Statin Use Among Patients with*. 26(9).
- Wong, W. J., Thi, H., & Vu, T. (2025). *Hypertension in Adults With Diabetes in Southeast Asia : A Systematic Review*. 1–16. <https://doi.org/10.1111/jch.14936>